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Abstract
Background: Treatment options for oncological diseases have been enhanced by the advent of targeted therapies.
The point mutation of the BRAF gene at codon 600 (BRAF V600E) is found in several tumor entities and can be
approached with selective inhibitory antibodies. The BRAF inhibitor vemurafenib has demonstrated clinical efficacy
in patients with BRAF V600E-mutant melanoma brain metastases and in other cancer diseases. Therefore the BRAF
V600E mutation is a highly interesting oncological target in brain tumors.
Methods: This study assesses the BRAF V600E mutation status in 969 intracranial neoplasms using a tissue microarray
method and immunohistochemical staining with the mutation-specific VE-1 antibody, followed by sequencing of
positively stained cases.
Results: Out of 784 primary brain tumors seven cases with a BRAF V600E mutation were detected (7/784, 1 %). Six of
these cases were neuroepithelial tumors (6/667, 1 %) encompassing 2 astrocytomas WHO grade II (2/42, 5 %), 1
gliosarcoma WHO grade IV (1/75, 1 %) and 3 glioblastomas WHO grade IV (3/312, 1 %). Interestingly, all three
mutant glioblastomas showed epithelioid histopathological features. Patients with V600E mutated astrocytic
tumors were significantly younger (mean age 15.3 years) than wildtype cases (58.2 years). Among three rhabdoid
meningiomas, one case was mutated (1/3) while all other grade I-III meningiomas (1/116, 1 %) and all fifty vestibular
schwannomas analyzed were of wildtype status. The vast majority of the BRAF V600E mutations were found in cerebral
metastases of malignant melanomas and carcinomas (29/135, 22 %), with false-positive staining found in four breast
cancer cases and two non-small-cell lung carcinoma (NSCLC) samples.
Conclusions: Our data suggest routine screening for BRAF V600E mutations for glioblastomas WHO grade IV below
the age of 30, especially in glioblastomas with epithelioid features and in all rhabdoid meningiomas WHO grade III.
For colorectal carcinoma, thyroid cancer, malignant melanoma and gliomas BRAF V600E immunostaining is sufficient
for screening purposes. We also recommend routine immunohistochemical staining followed by sequencing validation
in rare CNS metastases or metastases of unknown primary.
Immunohistochemical analysis using mutation-specific antibodies on tissue microarrays is a feasible, time- and
cost-efficient approach to high-throughput screening for specific mutations in large tumor series but sequencing
validation is necessary in unexpected cases.
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Background
With the advent of deeper insights into the development
and molecular identity of tumors, targeted therapies have
become increasingly interesting and have shown efficacy in
several tumor entities [1, 2]. One of the best-studied targets
is the proto-oncogene B-Raf (BRAF) that encodes a serine/
threonine protein kinase of the RAS-RAF-MEK-ERK-MAP
kinase pathway. This highly regulated pathway controls cell
growth and can be disrupted by BRAF alterations, which
transform the BRAF kinase into a constitutively activated
form resulting in excessive cell proliferation and thus enab-
ling tumor growth [3]. Especially the BRAF V600E muta-
tion has been described in up to 7 % of human cancers [4].
This specific mutation causes an exchange of valine for
glutamine at position 600 of the amino acid sequence of
the protein kinase. It is a well-characterized target in ma-
lignant melanoma and can be found in approximately 66 %
of primary cases [4]. Direct targeting with B-Raf kinase
inhibitors such as vemurafenib or dabrafenib is an effective
new treatment option and has been approved for advanced
malignant melanomas harboring the BRAF V600E muta-
tion [5]. Recently, a mutation-specific monoclonal antibody
(VE-1) for the BRAF V600E mutation has been devel-
oped [6] and successfully validated in malignant melan-
oma, colorectal and papillary thyroid cancer as well as
non-small-cell lung carcinoma (NSCLC), pleomorphic
xanthoastrocytomas (PXA) [7–11].
In some glioma types the antibody is even considered
superior to sequencing [12]. Overall, BRAF mutations play
an important role in neurooncology. An analysis of 885
brain metastases revealed mutations in metastases of mel-
anoma (55.3 %), ovarian (6.7 %), colorectal (5.5 %), lung
(0.3 %) and thyroid (33.3 %) cancer [13]. Interestingly, the
frequency of BRAF mutations in primary lung cancer is
higher – an overview reported that 36 out of 883 NSCLCs
had BRAF V600E mutations [14]. Subsequent studies con-
firmed the lower frequency of V600E mutations in NSCLC
brain metastases, indicating that frequencies of V600E mu-
tated metastases in the brain might differ from those in
primary locations [15]. Approximately 10 % of all colorec-
tal cancer specimens carry the V600E mutation, but unfor-
tunately this tumor type does not respond well to inhibitor
treatment [16]. In papillary thyroid carcinomas the muta-
tion was reported to be present in about 45 % [17, 18] and
there is evidence that it has a negative prognostic impact
[19]. Both entities occasionally metastasize to the brain.
Data on mutation frequency in these brain metastases is
still limited.
BRAF signal alterations are also involved in primary
brain tumors. In 2008 a tandem-duplication at 7q34 was
identified, resulting in fusion of the previously uncharac-
terized gene KIAA1549 and the BRAF gene to create a
novel fusion oncogene [20]. While this fusion transcript
is relatively specific to one pediatric brain tumor, the
pilocytic astrocytoma (up to 70 % of the cases), a subse-
quent study of 1320 nervous system tumors revealed ex-
ceptionally high rates of BRAF V600E mutations in
pleomorphic xanthoastrocytomas (PXA) WHO grade II
(66 %) and III (65 %) as well as gangliogliomas WHO grade
I (18 %) and III (50 %). Moreover, the BRAF V600E muta-
tion was also found in 9 % of pilocytic astrocytomas, mutu-
ally exclusive with the KIAA1549-BRAF fusion and was
associated with extracerebellar location [21]. In PXA, recent
data indicate a favorable course for V600E mutated tumors
[22], while in ganglioglioma and diencephalic tumors it is
considered a negative prognostic factor [23, 24]. In pediatric
diffusely infiltrating astrocytomas BRAF V600E mutation
frequencies between 17 – 29 % have been reported in
smaller studies [25–28]. The high V600E frequency rates
in pediatric brain tumors were recently confirmed in a lar-
ger independent cohort [29].
As a consequence of these findings and the good out-
come in the therapy of malignant melanoma, several
reports of salvage kinase inhibitor treatment in V600E-
mutated, advanced cerebral tumor entities have been pub-
lished. One case of an anaplastic ganglioglioma of the
brainstem showed decrease in size and enhancement on
magnetic resonance imaging (MRI) controls after receiv-
ing vemurafenib combined with vinblastine [30]. Bautista
et al. presented 3 pediatric cases with BRAF mutated ma-
lignant gliomas. One out of 2 anaplastic gangliogliomas
and one anaplastic astrocytoma responded to vemurafe-
nib treatment [31]. In a case series of 4 advanced BRAF
V600E mutated PXAs WHO grade II vemurafenib was
applied as a salvage therapy. The treatment resulted in
disease stabilization in two cases and partial response
of one patient [32]. Another clinical response was ob-
served in a patient with a meningeal PXA with anaplas-
tic features and a BRAF V600E mutation [33]. Tumor
regression under vemurafenib was also reported in a
case of advanced pilomyxoid astrocytoma [34].
Even though unmasked as a rarity by several studies, the
BRAF V600E mutation in glioblastomas revealed interest-
ing aspects. Epithelioid glioblastomas may harbor a BRAF
V600E mutation in 50 % of the cases [35]. One case of a
pediatric glioblastoma with focal epithelioid features has
been reported where vemurafenib was applied after tumor
recurrence. Surprisingly, the 9-year old boy showed re-
gression of the enhancement of the V600E-mutated tumor
on subsequent MRIs [36]. Another recent case of a quick
recurring epithelioid glioblastoma underwent a second re-
section with adjuvant vemurafenib application after BRAF
V600E mutation was detected. The last report stated that
the patient was tumor free for 21 months [37]. Based on
promising results from in vitro application of BRAF
V600E inhibitory substances, further evaluation of BRAF
V600E treatment options in malignant astrocytoma was
suggested [38].
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Intracranial neoplasms as collected in this study are the
typical tumor entities encountered in a neurooncological
tumor board. Cases with primary central nervous system
(CNS) tumors and metastases in advanced stages, where
established therapies are exhausted, are regularly dis-
cussed for a possible inhibitory antibody treatment against
BRAF V600E mutated tumor cells. Treatment is estab-
lished and approved for metastasized malignant melan-
oma and, as stated above, numerous case reports suggest
efficacy in other advanced neurooncological tumor types.
The primary goal of this study was to assess the use-
fulness of the VE-1 antibody to detect V600E mutated
samples as a first step in neurooncological tumor routine
work up. Because of the expected differences in frequen-
cies, data of primary brain tumors and metastases are
presented separately.
A special emphasis was placed on brain metastases,
meningiomas, gliosarcomas and vestibular schwannomas
that were underrepresented in previous studies. Our aim
is to establish an age and histology-dependent rationale
regarding the choice of neurooncological tumor types
that should undergo routine BRAF V600E mutation
screening, thus allowing the possibility of targeted treat-
ment with kinase inhibitors and to determine the effi-
ciency of the BRAF mutation specific VE-1 antibody to
detect the V600E hotspot mutation successfully in arch-
ival specimens.
Methods
In total 969 brain tumors were analyzed including 667
neuroepithelial tumors, 117 meningiomas, 135 metastases
and 50 vestibular schwannomas. The detailed histopatho-
logical entities are listed in Table 1. Histological diagnosis
and grading for each tumor sample were performed ac-
cording to the current WHO classification system by at
least two, or in most cases three board-certified neuropa-
thologists (CH, CS, JS). Basic clinical characteristics of the
assessed cases (age at diagnosis and gender) were collected
and statistically analyzed (ANOVA followed by student t
for correlation) with the software JMP® Version 10.
(SAS Software, Cary, NC, USA). Archived paraffin em-
bedded tissue samples from the Institutes of Neuro-
pathology Tübingen and Göttingen were processed into
tissue microarray (TMA) blocks.
Hematoxylin and eosin (H&E) stains of each sample
were assessed beforehand and tumor areas most suitable
for sample cylinder extraction were marked. Representative
tumor cores were selected, excluding necrotic tumor areas,
inflammation, stroma-rich areas or infiltration borders.
The tissue sample size was 1 or 2 mm in diameter and in
most cases two donor cylinders were obtained and aligned
on recipient blocks using a conventional tissue microar-
rayer (Beecher Instruments, Sun Prairie, Wisconsin, USA).
The newly constructed TMA blocks were cut in 4 μm
slices, dried at 80 °C for 15 min and stained immediately.
Immunohistochemical staining was performed on a
Ventana BenchMark immunostainer (Ventana Medical
Systems, Tucson, USA). The Ventana staining procedure
included pretreatment with cell conditioner 1 (pH 8) for
72 min (VE-1), followed by incubation with primary anti-
bodies (VE-1 dilution 1:5) at 37 °C for 32 min to mark
BRAF V600E mutated tumor cells [6]. The anti-BRAF
V600E (VE-1 clone, a kind gift from Dr. Capper, Neuro-
pathology Heidelberg) antibody is a mutation-specific
mouse monoclonal antibody that was raised against a syn-
thetic peptide representing the BRAF V600E mutated
amino acid sequence from amino acids 596 to 606 (GLA-
TEKSRWSG). The same antibody is commercially avail-
able by Ventana Roche (catalogue number 790-4855).
Antibody incubation was followed by OptiView HQ
Universal Linker for 12 min, incubation with OptiView
HRP Multimer for 12 min. Stains were counterstained
with one drop of hematoxylin for 4 min. Melanoma sam-
ples with validated BRAF V600E mutation served as posi-
tive control in each run. The stained TMA slides were
microscopically evaluated. BRAF V600E staining was con-
sidered positive, when more than 1 % of the visible tumor
cells were at least weakly immunoreactive for BRAF
V600E. Any type of isolated nuclear staining, weak stain-
ing of single interspersed cells, or staining of monocytes/
macrophages was scored negative. In 12 cases repeated
VE-1 staining on full slides was necessary, because either
positive controls included in each batch were not stained
sufficiently or a very weak unspecific background staining
was present.
All immunopositive samples identified by BRAF V600E
immunohistochemistry subsequently underwent Sanger se-
quencing for V600E mutation status except for melanoma
metastases, where the antibody has been validated previ-
ously. Tumor deoxyribonucleic acid (DNA) was extracted
from selected areas with sufficient tumor content on full
slides using the black Prep DNA Mini Kit (Analytik Jena,
Germany) according to manufacturer’s instructions. Amp-
lification of BRAF polymerase chain reaction (PCR) prod-
ucts was carried out with 200 ng of genomic DNA and the
following PCR primers: BRAF fwd: 5’-TGTAAAACGA
CGGCCAGTTCATAATGCTTGCTCTGATAGGA-3’ and
BRAF rev: 5’-CAGGAAACAGCTATGACCTAGCTCAG
CAGCATCTC-3’ (M13-tailed). PCR conditions were per-
formed with an initial denaturation at 95 °C for 5 min, de-
naturation at 95 °C for 45 s, annealing at 56 °C for 1.15 min
and extension at 72 °C for 1 min for 45 cycles followed by
final elongation at 72 °C for 7 min. For the PCR amplifica-
tion of the BRAF fragment the AmpliTaq Gold® DNA poly-
merase (Applied Biosystems) was used. Subsequent to the
PCR amplification PCR products were purified with Agen-
court AMPure Beads (Beckman Coulter) following the
manufacturer’s instructions. The PCR products were
Behling et al. Diagnostic Pathology  (2016) 11:55 Page 3 of 10
sequenced using a GenomeLab™ GeXP Genetic Analysis
System (Beckman Coulter).
Results
Thirty-six out of 969 (4 %) analyzed central nervous system
neoplasms were immunohistochemically positive for the
BRAF V600E mutation (Table 1). The majority of immuno-
positive cases showed moderate to strong cytoplasmic
staining of almost all tumor cells while endothelia as well as
inflammatory and other non-tumorous cells were spared
(Fig. 1). In neuroepithelial tumors, positive antibody stain-
ing was present in six out of 667 (<1 %) tumors. When
present, the necrotic and perinecrotic tumor areas in
immunopositive cases had a marked reduction of VE-1
staining. Direct sequencing for the BRAF V600E mutation
in isolated tumor DNA was used for confirmation of the
mutation in these tumors (Fig. 1). The mutated samples in-
cluded two diffuse astrocytomas WHO grade II (two out of
42 samples (4.76 %)) and 4 WHO grade IV tumors (three
out of 312 glioblastomas (0.96 %) and 1 out of 75 gliosarco-
mas (1.33 %)). According to a retrospective analysis of the
samples and patient characteristics, all three glioblastomas
showed epithelioid features and two were exceptionally
young compared to the average age of glioblastoma patients
(8, 22 and 70 years of age at time of diagnosis). The pa-
tient with the mutated gliosarcoma was 27 years old at the
time of diagnosis (Table 2). None of the wildtype glioblast-
omas exhibited epithelioid features in the histology. All
WHO grade III gliomas were immunonegative for VE-1
(36 anaplastic astrocytomas, 15 anaplastic oligoastrocy-
tomas, 40 anaplastic oligodendrogliomas and 13 ana-
plastic ependymomas). The two patients with mutated
diffuse astrocytomas WHO grade II were 16 and
17 years old, while all other low grade gliomas in our
cohort were immunonegative and had an average age of
46 years (12 oligoastrocytomas, 19 oligodendrogliomas




Neuroepithelial tumors: 6/667 0.90 54
Astrocytoma (WHO grade II) 2/42 4.76 44
Oligoastrocytoma (WHO grade II) 0/12 0.00 41










Glioblastoma (WHO grade IV) 3/312 0.96 60
Gliosarcoma (WHO grade IV) 1/75 1.33 62





















Meningeal tumors: 1/117 0.85 45
Meningioma (WHO grade I) 0/55 0.00 41
Meningothelial 0/28 0.00 40
Transitional 0/17 0.00 41
Fibrous 0/3 0.00 41
Psammomatous 0/3 0.00 48
Microcystic 0/2 0.00 45
Not otherwise specified 0/2 0.00 50
Meningioma (WHO grade II) 0/35 0.00 39
Atypical 0/26 0.00 35
Chordoid 0/2 0.00 43
CNS infiltration 0/2 0.00 45
Not otherwise specified 0/5 0.00 59
Meningioma (WHO grade III) 1/27 3.70 60
Anaplastic 0/24 0.00 62
Rhabdoid 1/3 33.33 36
Metastases: 29/135 21.48 57
Melanoma 24/58 41.38 56
NSCLC 0/29 0.00 59
Adeno Ca 0/22 0.00 59
Table 1 Frequency of BRAF V600E mutations in 969 CNS tumors
(Continued)
Squamous cell Ca 0/5 0.00 60
Not otherwise specified 0/2 0.00 58
Breast Ca 0/22 0.00 54
Colorectal Ca 2/4 50.00 51
Sarcoma 0/7 0.00 57
Prostate Ca 0/6 0.00 66
Renal clear cell Ca 0/3 0.00 71
Esophageal adeno Ca 1/2 50.00 46
Hepatcellular Ca 1/1 100.00 73
Papillary thyroid Ca 1/1 100.00 74
Parotid acinic cell Ca 0/1 0.00 41
Ovarian Ca 0/1 0.00 45
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and 46 ependymomas). The mean age of wildtype
astrocytic tumors (astrocytomas WHO grade II, ana-
plastic astrocytomas WHO grade III, glioblastomas and
gliosarcoma WHO grade IV) was 58.2 years (95 % con-
fidence interval: 56.8-59.5) while the mean age in BRAF
V600E mutated cases was 15.3 years (95 % CI: 3.6-27.1)
and thus significantly younger (student t-test, p <
0.0001). Additionally, 36 choroid plexus tumors as well
as 50 vestibular schwannomas were analyzed. None of
them showed evidence of a BRAF V600E mutation
(Table 1).
We also analyzed a broad spectrum of meningiomas of
different subtypes. All WHO grade I and II meningi-
omas were immunonegative (0/55 and 0/35, respectively,
Table 1) while one out of three rhabdoid meningiomas
WHO grade III was mutated, which was confirmed by
direct Sanger sequencing of the relevant case. The pa-
tient was 15 years of age at the time of diagnosis while
Fig. 1 BRAF V600E mutation analysis via immunohistochemistry and Sanger sequencing: BRAF V600E immunopositive high-grade glioma with
typical homogenous perinuclear staining of tumor cells (upper panel). Sanger sequencing of a BRAF V600E mutated sample of a rhabdoid meningioma
(lower panel)
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the other two VE-1 negative rhabdoid meningioma
cases were 45 and 47 years old. Extensive histopatho-
logical re-analysis of this case confirmed the diagnosis
of a rhabdoid meningioma. All other high-grade men-
ingiomas (24 anaplastic meningiomas WHO grade III)
were immunonegative and were from patients of older
age, the youngest patient being 38 years old at the time
of diagnosis.
Overall, one quarter of the cerebral metastases of this
study were immunopositive for the BRAF V600E muta-
tion (29/135, 21.48 %). As expected from previous data,
melanoma metastases showed a highe mutation rate with
41.38 % (24/58 cases). One case of a papillary thyroid
carcinoma and one hepatocellular carcinoma (HCC) cere-
bral metastasis were also VE-1 positive and sequencing
confirmed the V600E mutation. One out of two esopha-
geal adenocarcinoma metastases was also immunopositive
(50 %), as well as two out of four colorectal carcinoma
metastases (50 %). Again, in these cases sequencing con-
firmed the BRAF V600E mutation. Cerebral metastases of
different sarcoma types (0/7), prostate cancer (0/6), renal
clear cell carcinomas (0/3) as well as one ovarian carcin-
oma and one parotid acinic cell carcinoma were all VE-1
negative. Out of 22 breast cancer metastases, four cases
showed weak to moderate immunohistochemical staining
for VE-1. However, Sanger sequencing revealed these
breast cancer metastases to be non-mutated for BRAF at
codon 600 (0/22). There were also two NSCLC adenocar-
cinoma metastases that were weakly immunopositive for
VE-1, but were identified as wildtype after sequencing. All
29 NSCLC metastases remained non-mutated. In contrast
to these six false positive metastases, immunopositivity
and Sanger sequencing were always concordant in all
neuroepithelial tumor samples except for one gliosarcoma
with very weak and diffuse unspecific VE-1 immunoreac-
tivity in the mesenchymal tumor component.
Discussion
The BRAF V600E mutation is rarely found in neuroepi-
thelial tumors and its exact role in this context is un-
clear. Apart from one large study [21] a detailed clinical
description and frequency of BRAF mutated cases has
not been performed. Additionally, some intracranial
tumor types remain that have not yet been assessed for
BRAF V600E mutation status or the number of cases
analyzed in previous studies was restricted to a few sam-
ples. Since the B-raf kinase inhibitor therapy poses a po-
tential effective treatment option, a wide screening for
mutations in different tumor entities is essential to de-
termine tumor types amenable to treatment with tar-
geted therapies. Therefore a relatively large number of
gliosarcomas, meningiomas, choroid plexus tumors and
non-melanoma brain metastases were included and ana-
lyzed in our cohort.
The role of BRAF mutations in primary central ner-
vous system tumors has been addressed by several stud-
ies that mostly showed that the aberration is a rare event
in gliomas. In glioblastoma the mutation frequency in
the literature ranges from 2–6 %. The few patients re-
ported with mutated glioblastomas were exceptionally
young [21, 39–41]. No mutated grade II or III glioma
has been found in these studies and unfortunately, the
detailed histomorphology of mutated glioblastomas was
not described. In our series the frequency with less than
1 % (3/312) was lower than previously reported. Combin-
ing the data from all four studies including the current
one, out of 505 glioblastomas analyzed in total only 8 were
BRAF V600E mutated (1.5 % of all tumors classified as
glioblastomas WHO grade IV).
Interestingly, all of our three immunopositive cases
showed epithelioid features and two cases were excep-
tionally young at the time of diagnosis. It has been re-
ported that the rare epithelioid glioblastoma might be
related to PXAs and harbor the BRAF V600E mutation
at similar frequency (~50 % of the cases). Furthermore
BRAF V600E mutated gliomas are almost exclusively
seen in the pediatric population [21, 39].
This combined data indicates that all glioblastomas with
epithelioid morphology or occurring below the age of
30 years may carry V600E mutations. As shown above, pa-
tients suffering from an astrocytoma with a BRAF V600E
mutation are significantly younger at the time of diagnosis
and using the upper 95 % confidence interval of the mu-
tated cases, a cut off at 30 years for screening is statistically
supported. Further studies are necessary to allow deeper
insights into the gliomagenesis of this special tumor entity
and their relation to PXA. Consistent with the previous
data from Schindler et al. and Gierke et al. we did not find
any V600E positive ependymal or choroid plexus tumor in
133 samples analyzed, indicating that V600E mutations
are absent in these neoplasms [21, 29].
Data regarding BRAF analysis in meningiomas is lim-
ited. Schindler et al. previously analyzed 75 meningiomas
without evidence for a V600E mutation [21]. Of our 117
meningeal tumors, only one case harbored a BRAF V600E
Table 2 Age of BRAF V600E mutated neuroepithelial and
meningeal tumors
Histopathology Age BRAF V600E Mt
Epithelioid glioblastoma (WHO grade IV) 8 Yes
Epithelioid glioblastoma (WHO grade IV) 70 Yes
Epithelioid glioblastoma (WHO grade IV) 22 Yes
Gliosarcoma (WHO grade IV) 27 Yes
Diffuse astrocytoma (WHO grade II) 16 Yes
Diffuse astrocytoma (WHO grade II) 17 Yes
Rhabdoid meningioma (WHO grade III) 15 Yes
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mutation. This case was one of three rhabdoid meningi-
omas WHO grade III and of exceptionally young age (15
compared to 45 and 47 years). A pleomorphic xanthoas-
trocytoma or other potential differential diagnoses were
ruled out by extensive immunohistochemistry reworking
of the cases. All other anaplastic meningiomas WHO
grade III of this cohort showed no evidence of V600E mu-
tation (0/24). Rhabdoid meningiomas may also display
some epithelial qualities of the tumor cells on histopatho-
logical examination, similar to the epithelioid glioblastoma
variant, but these tumors can be easily distinguished by
immunohistochemistry for epithelial membrane antigen
and glial fibrillary acidic protein (GFAP) [42, 43]. Just re-
cently, a case of a BRAF mutated, metastasizing rhabdoid
meningioma in a comatose child discovered by panel se-
quencing was reported [44]. Treatment with a kinase in-
hibitor showed efficacy by clinical improvement. There is
growing evidence that BRAF V600E mutated meningeal
tumors may respond to this selective inhibitor therapy
[33]. This underlines the importance of BRAF mutation
testing for high-grade meningiomas, especially when rhab-
doid features are present. Consistent with the previous
data from Schindler et al. who analyzed 14 schwannomas,
we also found no mutation in 50 vestibular schwannomas,
indicating that BRAF mutations are absent or very rare in
these tumors [21].
Among the cerebral metastases, a total of 29 out of 135
tumors were BRAF V600E mutated and detected by the
mutation-specific VE-1 antibody. We found a mutation
frequency in cerebral melanoma metastases of 41.38 % (24/
58), which is in line with the incidence reported in the lit-
erature (55.3 %) [13]. The mutation rate in papillary thyroid
carcinomas has been described to be around 45 % [17, 18].
Capper et al. showed a slightly lower rate in cerebral metas-
tases with 33 % [13]. We assessed the only one metastatic
case in our cohort, which was BRAF V600E mutated.
Interestingly, we found four weakly immunopositive
breast cancer metastases, which were all of wildtype
status after sequencing (overall 0/22). This data is in
line with other studies on cerebral metastases that sug-
gested absence of this mutation in metastasized breast
cancer (in 117 [13] and seven cases [15]). Additionally,
two non-small cell lung cancer (NSCLC) adenocarcin-
oma metastases were immunopositive but did not show
a BRAF V600E mutation in the sequencing analysis. In
NSCLC the mutation rate for primary tumors was de-
scribed as 4 % in a large study by Cardarella et al. [14]. Vil-
lalva et al. could not find a single mutated NSCLC cerebral
metastasis in 77 cases [15], while Capper et al. showed only
one out of 355 NSCLCs to be mutated. Out of these 355
cases there were 169 adenocarcinomas, which were all
immunonegative [13]. All 29 NSCLSs of our study were
adenocarcinomas and were immunonegative, in line with
previous data.
We have no explanation for the false immunopositivity
of these cases, but we were able to rule out sequencing
failure since all samples had at least 80 % tumor content.
Although the mutation-specific antibody has been suc-
cessfully validated in several types of cancer [6–11], false-
positive staining with the VE-1 antibody has been reported
previously for pituitary adenomas [45]. In this case, the
positive VE-1 staining was confirmed by independent la-
boratories but direct sequencing of BRAF and the putative
homologs A-Raf proto-oncogene serine/threonine protein
kinase (ARAF) and Raf-1 proto-oncogene serine/threo-
nine protein kinase (CRAF) ruled out cross reactivity [45].
It is likely that a similar cross reactivity to an unknown
homolog may exist in breast adenocarcinomas although
false-positive staining was weaker compared to some of
the pituitary adenomas. Our data suggest that, while
VE-1 may represent a specific tool for detecting BRAF
V600E mutations in validated tumors, such as melan-
oma or colorectal cancer metastases, it is unsuitable for
detecting potential BRAF V600E mutations in breast
cancer, lung adenocarcinomas and pituitary adenomas,
further supporting that the specificity of VE-1 should
be thoroughly examined for each tumor entity by paral-
leled genetic mutation analysis prior to routine applica-
tion for research or diagnostics.
The mutation rate in primary colorectal carcinomas
has been described in a large study by Roth et al. with
7.9 % [46]. A different study focusing on colorectal can-
cer reported up to 13 % BRAF V600E mutated tumors
[47]. Capper et al. were able to reveal 5.5 % of cerebral
metastases to be mutated as well (4/72 [13]). Just as re-
ported by Villalva et al. in 2013, we found two out of
four cerebral metastases to be immunopositive for the
BRAF V600E mutation [15]. It is possible, that the rate
may be exceptionally high due to our small sample size.
Further studies with larger numbers of colorectal cancer
brain metastases are needed to determine the actual fre-
quency of V600E mutations in these tumors.
One cerebral metastasis of a hepatocellular carcinoma
was also included in this study and was immunopositive
for BRAF V600E (confirmed by sequencing). In the ana-
lysis by Capper et al. five cerebral metastases of HCC were
all immunonegative [13]. The BRAF V600E mutation has
been described in a series of Italian hepatocellular carcin-
omas and discussed as one of the driving mutations in
carcinogenesis [48]. The kinase inhibitor sorafenib is an
established targeted therapy option in hepatocellular car-
cinoma in loco typico and has been approved by the
American Food and Drug Administration (FDA) [49, 50].
Our case is the first BRAF mutated cerebral metastasis of
a hepatocellular carcinoma that has been reported in the
literature. To our best knowledge, there are no reports of
hepatocellular carcinomas treated with BRAF specific kin-
ase inhibitors such as vemurafenib or dabrafenib.
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No BRAF V600E mutation was found in a series of 534
gastroesophageal tumors by Preusser et al. [51]. Three
cases of another series were also negative [13]. In contrary
to these findings, one out of two assessed esophageal
adenocarcinoma brain metastases of this study was mu-
tated. The tumor origin was verified via strong immuno-
positivity for CDX2 (Caudal type homeobox 2, a marker
for intestinal epithelial cells) in both cases and review of
primary tumors. This data indicates that V600E mutations
are not restricted to the lower intestinal tract and all brain
metastases with CK20 (Cytokeratin 20, a marker for intes-
tinal epithelial cells) and CDX2 immunoprofile should be
examined for a possible V600E mutation.
Limitations of this study
The tissue microarrays were constructed by selecting rep-
resentative tumor cores excluding necrotic tumor areas,
inflammation, stroma-rich areas or infiltration borders. In
most cases two donor cylinders were obtained to assess
potential morphologic heterogeneity of tumors and aligned
on recipient blocks. Instead of using the more commonly
used smaller 600 μm sized punches we used 1000 μm and,
when possible, 2000 μm sized punches in our study to ob-
tain more available tumor tissue for staining examination.
We did not observe a heterogenous staining in tumor
areas of mutated samples. Together with the rather large
size of the samples and the confirmation of wildtype se-
quencing in selected negative samples a false negative
staining is highly unlikely but remains possible. According
to our study design, only VE-1 positive cases were se-
quenced, so the rate of potential false-negative cases was
not assessed with this method. Besides the reported four
false-positive breast cancer and two NSCLC adenocarcin-
oma metastases, only one gliosarcoma showed very weak
immunopositivity of the mesenchymal component and
was of wildtype status after Sanger sequencing control.
Those tumors that were mutated and confirmed via se-
quencing usually had moderate to strong staining signal in
all tumor cells available on the TMA sample.
A high correlation of immunohistochemical results of
the VE-1 antibody with DNA-sequencing has been shown
recently by Dvorak and colleagues. A sensitivity of 98.6 %
and a specificity of 99.1 % were demonstrated in colorectal
and papillary thyroid carcinomas [8]. Similar rates were
described before in primary lung adenocarcinomas [9],
malignant melanomas [7] and pleomorphic xanthoastro-
cytomas [10].
However, technical problems with the VE-1 antibody
have been reported. Several studies revealed that the anti-
body is not reliable for the assessment of pituitary aden-
omas. It stained normal anterior pituitary tissue, while no
BRAF mutated case was detected via sequencing controls
[6, 45, 52, 53]. In colorectal carcinoma the antibody
showed no satisfactory correlation regarding routine usage
[54, 55]. A good correlation between the VE-1 antibody
immunohistochemistry and sequencing for BRAF V600E
mutations has been reported in brain metastases [13].
Kleinschmidt-DeMasters et al. experienced good reliability
of immunohistochemistry in gliomas compared to se-
quencing and also reported of homogenous staining. Only
unique cases with older tissue samples displayed some
heterogeneous areas and even staining intensity variability
from cell to cell [37]. Positive antibody staining in gliomas
can be directly attributed to neoplastic cells within non-
neoplastic background neuropil [12]. We experienced only
homogenous staining in our samples. A high staining spe-
cificity was observed in three glioblastomas and the posi-
tive meningioma.
Screening recommendations
Immunohistochemical screening should be considered in
selected cases, followed by sequencing validation in tumor
types with limited data on sensitivity and specificity or in
metastases for which the origin is not entirely clear. We
consider VE-1 immunostaining as a useful first step in
tumor samples to elucidate potential candidates to be se-
quenced in the next step, especially epithelioid glioblast-
omas, astrocytic tumors occurring below 30 years of age
and rhabdoid meningiomas. In tumor types with sufficient
validation data on immunohistochemistry and sequencing
available, i.e. melanoma, colorectal and thyroid carcinoma
and pleomorphic xanthoastrocytomas, VE-1 immuno-
staining might be sufficient to indicate BRAF V600E tar-
geted therapy.
Conclusion
The BRAF V600E mutation can enable a potentially ef-
fective targeted therapy in cerebral neoplasms. Thus im-
munohistochemical screening should be considered in
selected cases. For neoplasms where high rates of sensi-
tivity and specificity of VE-1 immunostaining have been
shown previously (colorectal carcinoma, thyroid cancer,
malignant melanoma, glioblastoma and pleomorphic
xanthoastrocytomas) BRAF V600E immunostaining is
sufficient for screening purposes. We also recommend
routine immunohistochemical staining followed by se-
quencing validation in rare CNS metastases or metastases
of unknown primary. Among brain tumors, besides the
already established entities such as pleomophic xanthoas-
trocytoma and ganglioglioma, especially epithelioid glio-
blastomas, astrocytic tumors occurring before the age of
30 years as well as rhabdoid meningiomas should undergo
routine BRAF V600E mutation analysis. Since the poten-
tial of the targeted therapy with kinase inhibitors has been
shown in several exemplary case reports, the therapeutic
role of a BRAF targeted treatment in these tumors needs
further assessment. Immunohistochemical analysis using
mutation-specific VE-1 antibody on tissue microarrays is a
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feasible, time-efficient and cost-efficient approach to high-
throughput screening for BRAF V600E mutations in large
brain tumor series and metastases.
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